About
503(b) outsourced compounding
Areas of Focus
Categories
Generic DrugSoutheastern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
7,050
By Phase
NA: 1PHASE1: 2PHASE2: 1
By Status
UNKNOWN: 2COMPLETED: 2
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT04014283Collaborator
Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.
NAUnknown
7,000 participants
Started: Oct 31, 2014 · Completed: Nov 30, 2023
NCT00002098Lead Sponsor
Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients
PHASE1Completed
50 participants
NCT00002099Lead Sponsor
Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients
PHASE2Unknown
NCT00002100Lead Sponsor
Phase I/II Study of Curdlan Sulfate
PHASE1Completed
Locations (1)
Headquarters
Little Rock, AR, United States
Map
Loading map...